Khurram Malik believes there is a “dramatic” lack of legal CBD products in Canada.

The CEO of Biome Grow, a cannabis holding company with licensed pot operations in a number of Atlantic provinces, says his ongoing conversations with various provincial liquor control boards, specifically in Nova Scotia and Newfoundland and Labrador always ends up circling back to one topic — the complete dearth of cannabis products high in CBD content, versus the large demand for it.

“When recreational legalization was going to happen, I think many of the licensed producers focused too much on the THC side of the sector. Now we’re seeing there’s actually a huge demand for CBD,” Malik said.

Interest around cannabis stocks continues to rise as legal adult use sales pick up steam in Canada and California, and other U.S. states move to legalize either recreational or medical use of the plant.

Investors have directed much of their attention on production and distribution of dried flower used for smoking.

Over the past couple of years, the hype behind cannabis stocks has been building to an all-time high, with many company stock prices doubling and tripling in the first nine months of 2018. Although the last quarter of the year shook the foundations of many of the less serious cannabis investors, 2019 has already seen an excellent return to force. Just in January, global cannabis stocks increased 31 percent, a trend that’s poised to continue throughout the rest of the year.

Canopy Growth has big plans for its edibles and vape pen rollout

One measure of a stock’s volatility is called beta, which is defined as the covariance of the stock and the market (typically an index such as TSX Composite) divided by the variance of the market.

The Canadian cannabis stocks we’ve dug up today have had an average one-year beta 3.1, indicating they are likely to have strong price movements in the future. For reference, the closer a stock’s beta is to 1, the closer it follows market movements.

MRFR Reports Provides Prominent Analysis of Global Medical Marijuana Market report by geographical overview, major products, applications, and key players. The report utilizes historical trends of the Global Medical Marijuana Market and present statistics to derive.

Over the last decade or so, marijuana has been a key research subject for medical scientists, academicians, and researchers across the globe. The research centers around understanding the various therapeutics benefits that marijuana offers. There have been positive steps taken by law enforcement agencies and healthcare facilities to legalize the production and the sale of marijuana for medical requirements.

America’s licensed marijuana sellers are just getting started.

They have only a few stores and profits are scarce. Their Canadian-listed stocks—they can’t trade on U.S. exchanges as marijuana remains illegal under federal law—also trade at steep multiples of the nascent industry’s sales. Maybe that’s because they are mainly owned by giddy retail investors—or maybe that’s the risk of getting in on the ground floor of ventures that aim to become the Starbucks of marijuana.

Marijuana investors are bubbling over with excitement, and who can blame them as this once-taboo industry ramps up production and rolls out the red carpet for consumers.

Canada's nationwide recreational marijuana market opened last October; last week, we got results from Canada's two biggest marijuana companies that suggest the country's marijuana market represents a massive opportunity.

Cannabis is rapidly becoming a global financial concern as nations ranging from the U.S. to Canada to Colombia to Israel — to name just a few — are actively discussing how to best partner up and get in on this economic juggernaut. Those imminent marijuana enterprises worldwide will soon create the industry’s global supply chains, lower costs, and potentially lead to scientific research for the plant as medicine.